Instrument Inactif

Communiqués Nile Therapeutics, Inc. Other OTC

Actions

US6541451018

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

04/06	Capricor Therapeutics annonce des résultats positifs d'efficacité après 3 ans de l'étude de prolongation ouverte Hope-2 sur le CAP-1002 pour le traitement de la dystrophie musculaire de Duchenne	CI
17/05	CAPRICOR THERAPEUTICS, INC. : Oppenheimer maintient sa recommandation à l'achat	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy	04/06	AQ
Capricor: Q1 Earnings Snapshot	13/05	AQ
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	13/05	AQ
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	09/05	AQ
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences	08/05	AQ
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13	06/05	AQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24/04	AQ
Capricor Therapeutics to Present at Upcoming Investor Conferences	21/03	AQ
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	06/03	AQ
Capricor: Q4 Earnings Snapshot	29/02	AQ
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02	AQ
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy	27/02	AQ
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29	22/02	AQ
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization	20/02	AQ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2	24/01	AQ
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis	11/12	AQ
Capricor: Q3 Earnings Snapshot	14/11	AQ
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	14/11	AQ
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	14/11	AQ
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14	07/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Nile Therapeutics, Inc. Other OTC

Actions

US6541451018

Communiqués

Filtres